U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-Williams

Reuters11-28
U.S. RESEARCH ROUNDUP-Biogen, Deere & Co, Sherwin-Williams

Nov 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biogen, Deere & Co and Sherwin-Williams, on Friday.

HIGHLIGHTS

* Biogen BIIB.O: Jefferies raises target price to $210 from $190

* Deere & Co DE.N: Truist Securities raises target price to $612 from $609

* Sherwin-Williams Co SHW.N: Berenberg cuts target price to $392 from $407

Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical order.

* Acadia Realty Trust AKR.N: Truist Securities cuts target price to $22 from $23

* Arcutis Biotherapeutics Inc ARQT.O: Mizuho raises target price to $37 from $32

* Biogen BIIB.O: Jefferies raises target price to $210 from $190

* Cabot Corp CBT.N: JP Morgan cuts target price to $54 from $75

* Deere & Co DE.N: Raymond James cuts target price to $545 from $560

* Deere & Co DE.N: Truist Securities raises target price to $612 from $609

* Dillard's Inc DDS.N: UBS raises target price to $460 from $184

* Disc Medicine Inc IRON.O: Jefferies raises target price to $154 from $127

* Ecovyst ECVT.N: Deutsche Bank cuts target price to $11 from $14

* Flutter Entertainment Plc FLUT.N: UBS cuts target price to $320 from $340

* Macy's Inc M.N: Telsey Advisory Group raises target price to $22 from $17

* Sherwin-Williams Co SHW.N: Berenberg cuts target price to $392 from $407

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment